LongevityResearch strength: PreliminaryEvidence: Preliminary
Livagen
Livagen (Lys-Glu-Asp-Ala, KEDA)
Also known as: KEDA
A Khavinson tetrapeptide sold for liver and gut 'bioregulation'; preclinical work from one group only.
Overview
Livagen is marketed for liver and gastrointestinal aging. Its evidence consists of cell and animal experiments from the Khavinson institute with no independent replication, no human randomized trial and no pharmacokinetic data for any route.
Mechanism of action
Proposed epigenetic modulation of hepatocyte and immune-cell gene expression.
Key studies & citations
- Review2020
Peptide bioregulators: the Khavinson corpus (review)
Single-lineage evidence base.
Stem Cell Reviews and Reports
Frequently asked questions
Is there human data for Livagen?
No.